# Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults

> **NCT05171946** · PHASE1 · UNKNOWN · sponsor: **Iman Almansour** · enrollment: 30 (estimated)

## Conditions studied

- Safety
- Vaccine Reaction
- Vaccine Adverse Reaction
- Immunization; Infection

## Interventions

- **DRUG:** S.opt.FL COVID-19 pDNA vaccine
- **DRUG:** S.opt.FL COVID-19 pDNA vaccine
- **DRUG:** S.opt.FL COVID-19 pDNA vaccine

## Key facts

- **NCT ID:** NCT05171946
- **Lead sponsor:** Iman Almansour
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-20
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171946, "Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05171946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*